TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05534087
Drug: mFOLFIRINOX-FOLFIRI intensified chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (1) Modified FOLFIRINOX (mFOLFIRINOX) regimen: 6 cycles every 2 weeks~* Oxaliplatin 85mg/m2 IV infusion over 120 min D1~* Leucovorin 400mg/m2 IV (concurrently with oxaliplatin)~* Irinotecan 150mg/m2 IV infusion over 60-90 min D1~* 5-fluorouracil 2,400mg/m2 IV infusion continuously over 46-48h D1-2
Study: NCT05798845
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: toripalimab 240mg ivgtt d4, d24 (2 cycles)
Study: NCT05798845
Drug: Chemotherapy drug
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-squamous carcinoma: pemetrexed + platinum or paclitaxel + platinum Squamous carcinoma: paclitaxel + platinum or gemcitabine + platinum
Study: NCT05841381
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 17 cycles
Study: NCT05798845
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: toripalimab 240mg ivgtt d1, d22 (2 cycles)
Study: NCT05841381
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80mg/m2 per week for a total of 12 weeks
Study: NCT06637332
Drug: Daptomycin for Injection
Normalized name: Daptomycin for Injection
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin given by injection at a dose determined by the treating team but not to be less than 6mg/kg
Study: NCT06637332
Drug: Vancomycin (IV)
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin by injection to be given at a dose selected by the treating team to achieve a desired trough level or AUC-based target, as determined by local standards of care
Study: NCT05174884
Drug: 22.2 mg Etonogestrel (ENG)
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subdermal insertion of a single Casea S pellet (22.2 mg ENG) in healthy female participants
Study: NCT05174884
Drug: 44.4 mg Etonogestrel (ENG)
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subdermal insertion of a two Casea S pellet (44.4 mg ENG) in healthy female participants
Study: NCT06437353
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: First-line chemotherapy regimen:~* Paclitaxel: 175 mg/m², intravenous infusion, on day 1.~* Carboplatin: AUC 5, intravenous infusion, on day 1.~* Surufatinib：250 mg once daily, taken continuously.~Maintenance Therapy Regimen:~* Surufatinib: 250 mg once daily, taken continuously.~* Olaparib: 300 mg twice daily.
Study: NCT05950724
Drug: Etanercept Injection [Enbrel]
Normalized name: etanercept Injection [Enbrel]
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg subcutaneous injection
Study: NCT06534411
Drug: Cagrilintide
Normalized name: Cagrilintide
DrugBank: Cagrilintide (DB18887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive once-weekly cagrilintide subcutaneously.
Study: NCT06534411
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive once-weekly semaglutide subcutaneously.
Study: NCT06534411
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive once-weekly tirzepatide subcutaneously.
Study: NCT05828082
Drug: Tuvusertib
Normalized name: Tuvusertib
DrugBank: Tuvusertib (DB18790)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05775471
Drug: Enfortumab Vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05942027
Drug: Co-Enzyme Q10
Normalized name: Thrifty White Co-Enzyme Q10 100mg Capsule
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated with Coenzyme Q10 capsules (CoQ10) 200 mg/day.
Study: NCT05623345
Drug: Izokibep
Normalized name: Izokibep
DrugBank: Izokibep (DB19081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)
Study: NCT05623345
Drug: Placebo to izokibep
DrugBank: Izokibep (DB19081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: Solution for injection~Route of administration: Subcutaneous (SC)
Study: NCT06313008
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: eligible subjects were randomly and equally assigned to the empagliflozin add-on group (empagliflozin 10 mg/ day).
Study: NCT06313008
Drug: Vildagliptin 50 MG
Normalized name: vildagliptin 50 MG
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: eligible subjects were randomly and equally assigned to vildagliptin add-on group (vildagliptin 50 mg/day as the initial dose).
Study: NCT06245629
Drug: Bortezomib-bendamustine-melphalan
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The aim of this retrospective cohort study is to evaluate the efficacy and safety of the conditioning regimen BBM compared to HDM in the setting of relapsed multiple myeloma.
Study: NCT06462547
Drug: INZ-701
Normalized name: INZ-701
DrugBank: INZ-701 (DB17629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).
Study: NCT06518564
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Human IgG1 antibody, 20mL single-use vials, via intravenous (into the vein) infusion per protocol.
Study: NCT06518564
Drug: M1774
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ataxia Telangiectasia and Rad3-related protein (ATR) inhibitor, 30 and 50 mg capsules, taken orally per protocol.
Study: NCT05343013
Drug: TAS-102
Normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIven by PO
Study: NCT04835506
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: infliximab
Study: NCT06365970
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: An anti-cancer medication that helps to repair DNA when it becomes damaged, known as a PARP inhibitor.
Study: NCT06365970
Drug: Dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: An anti-cancer medication that is a programmed death receptor-1 -blocking monoclonal antibody.
Study: NCT06333561
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day
Study: NCT06333561
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg intravenously every 3 weeks
Study: NCT06333561
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg intravenously every 3 weeks
Study: NCT06333561
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg intravenously every 3 weeks
Study: NCT06333561
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg intravenously every 3 weeks
Study: NCT06178679
Drug: ST-100 (vezocolmitide)
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml
Study: NCT04880785
Drug: Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]
Normalized name: dolutegravir 50 MG / lamiVUDine 300 MG Oral Tablet [Dovato]
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: change of current antiretroviral treatment to DTG 50 mg/3TC 300 mg QD
Study: NCT04784104
Drug: Bupivacaine HCl 0.5% Injectable Solution
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
Study: NCT04784104
Drug: Prilocaine HCl 2% Injectable solution
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine and 2 ml saline with 5 mcg adrenaline per ml.)
Study: NCT04924179
Drug: Tislelizumab plus Fruquintinib and SBRT
Normalized name: Tislelizumab
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib:5mg ,qd,po, d1-d14, 21 days for a cycle;Tislelizumab Injection:200mg，IV,d1,21 days for a cycle;SBRT:8-10Gy×5F,qod,in 10 days.
Study: NCT06274528
Drug: Lemborexant 10 mg
Normalized name: lemborexant 10 MG
DrugBank: Lemborexant (DB11951)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Within FDA approved dose 10 mg; capsule; QD, 6 month duration
Study: NCT06274528
Drug: Lemborexant 20mg
DrugBank: Lemborexant (DB11951)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg; capsule; QD; 6 month duration
Study: NCT05637671
Drug: oxybutynin ER
Normalized name: Oxybutynin Chloride 5 MG Oral Tablet, Extended Release [OXYBUTYNIN ER]
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One study group will receive 10 mg of oxybutynin ER orally once daily for 12 weeks.
Study: NCT05637671
Drug: Paroxetine CR
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the other group will receive 12.5 mg of paroxetine CR orally once daily for 12 weeks.
Study: NCT05984368
Drug: BG136
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects injected with BG136 in Part 1 and Part 2
Study: NCT06447376
Drug: Siltuximab
Normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose of prophylactic siltuximab, 11mg/kg, started 1 hour prior (+/- 60 minutes) to the infusion of epcoritamab.
Study: NCT06175702
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose 1.5 mg/m2 at days 1, 8, 15 and 22
Study: NCT06175702
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg on days 1-2, 8-9,15-16 and 22-23
Study: NCT06175702
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg per day from 1 to up to 5 years
Study: NCT06175702
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2/ on days 1, 3 and 5 of consolidation with 2h infusion
Study: NCT06175702
Drug: Ponatinib
Normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg per day from consolidation start up to 5 years
Study: NCT06447376
Drug: Epcoritamab
Normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epcoritamab dosing for Diffuse Large B-cell Lymphoma Participants:~* Cycle 1, Day 1 = 0.16mg~* Cycle 1, Day 8 = 0.8mg~* Cycle 1, Day 15 = 48mg~* Cycle 1, Day 22 = 48mg~* Cycles 2 \& 3, Day 1 = 48mg~* Cycles 2 \& 3, Day 8 = 48mg~* Cycles 2 \& 3, Day 15 = 48mg~* Cycles 2 \& 3, Day 22 = 48mg~* Cycles 4-9, Day 1 = 48mg~* Cycles 4-9, Day 15 = 48mg~* Cycle 10+ , Day 1 = 48mg~Epcoritamab dosing for Follicular Lymphoma Participants:~* Cycle 1, Day 1 = 0.16mg~* Cycle 1, Day 8 = 0.8mg~* Cycle 1, Day 15 = 3mg~* Cycle 1, Day 22 = 48mg~* Cycle 2 \& 3, Day 1 = 48mg~* Cycle 2 \& 3, Day 8 = 48mg~* Cycle 2 \& 3, Day 15 = 48mg~* Cycle 2 \& 3, Day 22 = 48mg~* Cycle 4-9, Day 1 = 48mg~* Cycle 4-9, Day 15 = 48mg~* Cycle 10+ , Day 1 = 48mg
Study: NCT06175702
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2 intravenous on days -7, -6, -5 y -4 before alloSCT (alternative to cyclophosphamide)
Study: NCT06544577
Drug: ELacestrant
Normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 345 mg/day once daily oral dosing
Study: NCT05471700
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive Azacitidine 75 mg/m2 on days 1-7.Each course is 28 days long.
Study: NCT05471700
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects would receive Venetoclax once daily by oral. The doses of Venetoclax is 100 mg on Day 1, 200 mg on Day 2, reaching a target dose of 400 mg on Day 3 and continuing through Day 28. Each course is 28 days long.
Study: NCT05776862
Drug: Ursolic Acid
Normalized name: Ursolic Acid
DrugBank: Ursolic acid (DB15588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take an oral 400mg (8 capsules - 4 in the morning/200mg and 4 at night/200mg) supplement of UA every day for 12 weeks.
Study: NCT04824365
Drug: Sodium Pyruvate
Normalized name: Sodium Pyruvate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will use a sodium pyruvate nasal spray 3x daily for 14 days.
Study: NCT05407324
Drug: Dazucorilant 300 mg
Normalized name: Dazucorilant
DrugBank: Dazucorilant (DB18025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of dazucorilant will be administered once daily in 4 softgel capsules of 75 mg dazucorilant/capsule.
Study: NCT05407324
Drug: Dazucorilant 150 mg
Normalized name: Dazucorilant
DrugBank: Dazucorilant (DB18025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dazucorilant and placebo will be administered once daily in 4 softgel capsules, 2 capsules with 75 mg dazucorilant/capsule and 2 capsules of placebo equivalent.
Study: NCT04792515
Drug: Camrelizumab combined with SOX/ or apatinib
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab: every 3 weeks (21 days) was given as one administration cycle. 200mg was given intravenously on the first day of each cycle. Dose adjustment is not allowed. Delayed administration is allowed.~Apatinib mesylate: 250mg, qd, stopped 28 days before surgery, and can be used by the investigator according to the patient's recovery 28 days after surgery.~Chemotherapy: The SOX regimen consisted of one cycle every 3 weeks (21 days).Dose adjustment is allowed. Delayed administration is allowed.~Oxaliplatin (OXA) : 130mg/m2, intravenous infusion, d1, infusion more than 2 hours.~Tigio Capsules (S-1) : Take orally after breakfast and dinner, twice daily, d1-14.~The dosing time window is ±3 days, but within 72 hours before each dosing, subjects must complete an examination that includes all clinical requirements to assess tolerance for continued dosing.
Study: NCT05953376
Drug: Calcium Gluconate
Normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: There will be 2 study arms, one will receive 2g IV calcium with the initial transfusion and the other will only receive calcium supplementation based on routine ionized calcium levels and/or physician discretion.
Study: NCT04043598
Drug: 0.9% Sodium-chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
Study: NCT00501579
Drug: Difluprednate
Normalized name: Difluprednate
DrugBank: Difluprednate (DB06781)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05800860
Drug: GH001
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH001 administered via inhalation
Study: NCT05093322
Drug: Surufatinib in combination with Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Surufatinib in combination with Gemcitabine
Study: NCT04557085
Drug: Cenobamate
Normalized name: Cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cenobamate tablets
Study: NCT05732402
Drug: Povetacicept
Normalized name: Povetacicept
DrugBank: Povetacicept (DB18996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous injection every 4 weeks
Study: NCT05932862
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib administered orally twice daily.
Study: NCT06335173
Drug: sabirnetug
Normalized name: Sabirnetug
DrugBank: Sabirnetug (DB19438)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sabirnetug
Study: NCT05468138
Drug: SOX
Normalized name: Vasoxyl
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Tegafur-Gimeracil-Oteracil Potassium The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.~Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
Study: NCT05468138
Drug: PD-1 antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab at a dose of 200 mg every 3 weeks for 16 cycles or Nivolumab at a dose of 360 mg every 3 weeks for 16 cycles
Study: NCT05565417
Drug: IMT-009
Normalized name: IMT 504
DrugBank: IMT504 (DB17792)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an IV infusion of IMT-009 on Day 1 during each 21-day cycle.
Study: NCT03668041
Drug: Trazodone
Normalized name: Trazodone
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trazodone is approved by the Food and Drug Administration (FDA) for treating major depression in adults but not for PTSD. Although trazodone has not been approved by the FDA to treat insomnia or PTSD, some doctors have tried it for these purposes. The doses in this study will be lower than the doses used to treat depression.
Study: NCT03668041
Drug: Eszopiclone
Normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eszopiclone is approved by the FDA for treating insomnia, but it's unknown if eszopiclone can help treat insomnia when it's related to PTSD. Some doctors have tried it for this purpose. The doses in this study will be the same as the doses used to treat insomnia. A small study found it to be helpful for treating patients with PTSD.
Study: NCT06555419
Drug: Nusinersen
Normalized name: Nusinersen
DrugBank: Nusinersen (DB13161)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as specified in the treatment arm.
Study: NCT06055075
Drug: Forimtamig
Normalized name: Forimtamig
DrugBank: Forimtamig (DB19015)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.
Study: NCT06055075
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib will be administered via IV infusion in combination with forimtamig.
Study: NCT06055075
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab will be administered via SC injection in combination with forimtamig.
Study: NCT06530030
Drug: efanesoctocog alfa
Normalized name: Efanesoctocog alfa
DrugBank: Efanesoctocog alfa (DB16662)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment decisions must be made independent of study participation and study-related visits/assessments are not intended to inform treatment decisions. No study medication is provided as part of study participation.
Study: NCT05554848
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine 0.5 µg/kg diluted in 50 mL of normal saline intravenously over 20 minutes, After induction followed by 0.5 µg/kg per hour infusion for 72 hours postoperatively or ready for extubation prior to 72 hour time period
Study: NCT05554848
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release. with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day.
Study: NCT05315258
Drug: Tebentafusp
Normalized name: Tebentafusp
DrugBank: Tebentafusp (DB15283)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tebentafusp supplied as concentrate for solution for infusion and diluted prior to administration. 0.2 mg/mL drug product will be provided as a sterile, refrigerated solution in glass vials.
Study: NCT05577702
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an intravenous infusion
Study: NCT05577702
Drug: Ociperlimab
Normalized name: Ociperlimab
DrugBank: Ociperlimab (DB18947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an intravenous infusion
Study: NCT05577702
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as an intravenous infusion
Study: NCT05577702
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as an intravenous infusion
Study: NCT05577702
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as an intravenous infusion
Study: NCT05577702
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as an intravenous infusion
Study: NCT05826353
Drug: Ripasudil
Normalized name: ripasudil
DrugBank: Ripasudil (DB13165)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: K-321 ophthalmic solution